Panitumumab Induced Paronychia and Trichomegaly

Oktay Ünsal, Osman Sütçüoğlu, Nuriye Özdemir

Department of Medical Oncology, Gazi University Faculty of Medicine, Ankara, Türkiye

Panitumumab is a recombinant, fully humanized IgG2 monoclonal antibody that targets the epidermal growth factor receptor (EGFR). Panitumumab is indicated in patients with metastatic colorectal cancer with progressive refractory disease. It is well known that targeted therapies are well tolerated; however, they may cause different toxicities than conventional chemotherapeutic agents. Nail-related adverse effects are frequently observed with EGFR inhibitors (EGFRIs). So far, few case reports have been published on the nail-related adverse effects of EGFRIs. While paronychia is a nail-related adverse effect of panitumumab, nail toxicity is one of the distinctive dermatological adverse effects of targeted therapies, especially EGFRIs. Trichomegaly is another very rare adverse effect.

A 55-year-old female patient was admitted to the clinic with ileus in 2021. Metastasis was detected in the liver during the operation. The colostomy was opened. The patient was diagnosed with colon cancer (T4N2M1 - Stage IV). Upon detection of N-Ras, K-Ras and BRAF wild-type in the pathological examination, FOLFOX-panitumumab treatment was initiated. After the third cycle of the treatment, the patient developed a grade 2 papulopustular rash. Skin lesions were regressed with medical treatment. The treatment was continued because the patient had partial response in the follow-up imaging at the 3rd month. In the 5th month of treatment, the patient presented with edema and painful erythema in the nail folds of the hands and left foot. The patient had paronychia and eyebrow elongation in both hands and left foot (Fig. 1, 2) (Grade 2). Panitumumab treatment was discontinued. The patient was started on antibiotic therapy. Treatment with FOLFOX was continued after the patient had a partial response.
The clinical features of EGFRI-induced nail and eyelash toxicity will become better understood as more case reports are published.

**Peer-review:** Externally peer-reviewed.

**Informed Consent:** Written informed consent was obtained from patients who participated in this study.

**REFERENCES**


2. Lacouture M, Sibaud V. Toxic side effects of targeted therapies and immunotherapies affecting the skin, oral mucosa, hair, and nails. Am J Clin Dermatol 2018; 19(S1): 31–9. [CrossRef]